[PRESS RELEASE] – BOCA RATON, Fla., May 28, 2026 – Jushi Holdings Inc., a vertically integrated, multistate cannabis operator, announced that it has submitted applications to the U.S. Drug Enforcement Administration (DEA) seeking registration for certain state-licensed medical marijuana operations under the federal framework established following the rescheduling of medical marijuana to Schedule III under the Controlled Substances Act.
“Pursuing DEA registration is an important milestone for Jushi and the medical patients we serve,” Jushi CEO Jim Cacioppo said. “We are focused on operating at the highest regulatory standards and believe this process represents a meaningful step toward a more integrated and transparent national framework for medical cannabis.”
In connection with the reclassification of medical marijuana produced by state-licensed operators to Schedule III, the DEA introduced a streamlined registration pathway for qualified state-licensed medical marijuana operators. This process enables applicants to seek federal registration in connection with the manufacture, distribution and dispensing of Schedule III medical cannabis products, while relying on existing state medical licenses as part of the qualification process. For operators that submit applications within the initial 60-day filing window, registrations may be granted on an expedited basis unless otherwise notified by the DEA.
Jushi believes this framework reflects growing federal recognition of the strength and oversight of state medical cannabis programs and provides a pathway toward greater alignment between state and federal regulation. The company’s applications are intended to position Jushi to participate in this evolving regulatory structure while continuing to serve medical patients in accordance with applicable state laws.
“This is an important step for the industry and reinforces what we have consistently heard from our patients about their experience with medical cannabis,” Cacioppo said. “We look forward to engaging with regulators as this framework develops and supporting continued progress in research, patient access, and responsible oversight of medical cannabis in the United States.”
